Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median ...
PDS Biotechnology: Continuing The Holding Pattern
PDS Biotechnology's HPV-directed immunotherapy is sparking optimism in the biotech industry. Click here to find out why I am ...
GlobalData on MSN1d
EMA CHMP recommends MSD’s KEYTRUDA for gynaecological cancers
Committee for Medicinal Products for Human Use (CHMP) has recommended approval of MSD’s KEYTRUDA for two gynaecological ...
Cure Today4d
Keytruda Improves Disease-Free Survival in Some With Urothelial Carcinoma
Among patients with high-risk muscle-invasive urothelial carcinoma, postsurgical Keytruda extended the time some lived ...
Merck Gets European Panel Backing for Keytruda in Two Gynecologic Cancers
Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.
The Clermont Sun5d
KWVA Chapter #121 Presents POW/MIA Recognition Poster
Chapter #121 (Greater Cincinnati) presented the National POW/MIA Recognition Day September 20, 2024 Poster to Clermont ...
New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma
Results from triple combination of efti, radiotherapy and KEYTRUDA® (pembrolizumab) to be presented at the Connective Tissue Oncology Society ...